Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USTR’s Special 301 Report Goes After India And China On IP

Executive Summary

India and China once again appear prominently on the USTR’s priority watch list in its annual ‘Special 301’ report on international intellectual-property standards, alongside nine other countries. Meanwhile, Canada has been moved to the regular watch list after striking the USMCA trade deal with the US.

You may also be interested in...



China Commits To Patent Linkage And Extensions In US Trade Deal

The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions. 

China Commits To Patent Linkage And Extensions

The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions. 

UK Opposition Would Fight TRIPS-Plus Provisions

The UK’s main opposition party, Labour, says it would resist US pressure to raise intellectual-property protections for pharmaceuticals. And it wants to support other countries in ensuring trade negotiations do not result in stronger IP rights globally.

Related Content

Topics

UsernamePublicRestriction

Register

GB140285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel